MAY 11, 2016 01:30 PM PDT

Precision Medicine - Moving From Pilot To Production Deployment

  • Chief Executive Officer, Genospace
      Mick's 15+ year career has tracked the path of genomics from basic research to clinical care. Over this time he has held leadership positions in academia and industry, and has developed informatics solutions for pharma/biotech R&D, ag-bio, and academic, government, and community healthcare providers. Prior to launching Genospace, he and partner John Quackenbush established the Center for Cancer Computational Biology at the Dana-Farber Cancer Institute. Mick began his career at Lion Bioscience Research Inc. and UK-based informatics provider InforSense.

      Mick earned a BS in computer science and a BA in molecular biology from the University of Colorado at Boulder.


    The clinical utility of high-dimensional molecular profiling has been provisionally established in several domains of medicine.  Today, interrogation of scores of genes and even whole exomes and genomes is an increasingly common practice that is informing diagnostic, theranostic, reproductive and other decisions by patients and physicians. Progress has been substantial, but vast potential remains untapped.
    As seen in biological research, genomic profiling technologies will proliferate in the clinic, providing insight across a myriad of molecular actors, processes, tissues and time points.  Indeed laboratory medicine is evolving from a bench science to an information science.
    One key objective of this presentation is to identify common challenges and roadblocks faced in deploying precision medicine programs at scale: Integrating the numerous complex and fragmented data sources necessary to inform clinical reporting; structuring biomarker and other association details such that they can be appropriately matched to observed events; and meeting the performance requirements necessary to support highly interconnected operational clinical systems necessary at high volumes. Here we will present specific technical solutions that can help move these programs from pilot to full production deployment.
    Beyond the immediate clinical utility, a remarkable aspect of precision medicine is the ability to apply aggregated data sets for a whole host of applications across the spectrum of research, development and clinical care.
    The second objective will be to explore examples of these myriad additional uses, and to discuss how a new breed of technical capabilities can provide the data agility necessary to maximize the value of these data assets.
    Finally, we will explore why molecular medicine is an ideal proving ground for the data agility the entire healthcare system so urgently needs.

    Show Resources
    Loading Comments...